Background: Bipolar disorder (BD), especially BD-II, is frequently comorbid with alcohol dependence. Because BD-II and alcohol dependence are neurodegenerative disorders, agents with antiinflammatory and neurotrophic effects might provide effective therapy. We investigated whether add-on memantine to regular valproic acid treatment ameliorated clinical symptoms, reduced alcohol use, and cytokine levels, and increased plasma brain-derived neurotrophic factor (BDNF) in BD-II patients with comorbid alcohol dependence.
B
IPOLAR II DISORDER (BD-II) is a subtype of BD characterized as recurrent episodes of depression and hypomania (Phillips and Kupfer, 2013 ) BD-II is often misdiagnosed because the diagnosis is frequently made based on recollections of past hypomania when patients present with symptoms of depression (Benazzi, 2001; Benazzi and Akiskal, 2003) . Therefore, BD-II is often ineffectively treated (Ghaemi et al., 2000) . Patients with BD-II have a greater risk of suicide (Rihmer and Pestality, 1999) , a prolonged clinical course, more mood episodes, more major and minor depressive episodes, and shorter interepisode intervals, than do patients with BD-I (Judd et al., 2003; Pallanti et al., 1999) .
Patients with BD frequently have comorbid alcohol use disorders (AUDs) (Di Florio et al., 2014) , especially patients with BD-II (Simhandl et al., 2016) . Irritable and hyperthymic temperaments might contribute to AUDs in BD (Singh et al., 2015) . Comorbid AUDs in BD worsened the clinical presentation with higher rates of mixed episodes, rapid cycling, and increased symptom severity (Frye and Salloum, 2006) . In addition, we previously reported (Shan et al., 2011 ) that even in the interepisode state, BD-II patients comorbid with AUDs performed poorly on verbal, visual, and working memory, psychomotor speed, and attention tests than did BD-II patients without AUDs and normal healthy controls.
BD is proposed as a "neurodegenerative" disease etiologically similar to Alzheimer's dementia by sharing common neurobiology including brain regions, mechanisms, genes, and epigenetic outcomes. Neuroimaging studies showed, in the progression of both BD and Alzheimer's disease, structural and functional alterations, which link to cognitive impairments (Correa-Velloso et al., 2018) . BD has been proposed to represent a prodromal state of frontotemporal dementia as well (Papazacharias et al., 2017) . Evidence indicates that BD leads to premature brain aging (Altamura et al., 2015) . In addition, neurodegenerative outcome has been demonstrated in autopsy from patients with BD such as argyrophilic grain-type tauopathy and Lewy body-related alpha-synucleinopathy (Shioya et al., 2015) . On the other hand, alcohol is certainly a toxic substance which may lead to brain atrophy. Therefore, comorbid BD and AUDs might lead to detrimental effects likely to increase toxins and nerve damage in various brain areas. On the other hand, neuroinflammation and microglia activation, which release a wide range of pro-inflammatory cytokines, have been related to onset and progression of BD (Naaldijk et al., 2016; Stertz et al., 2013) . The pro-inflammatory cytokines including tumor necrosis factor alpha (TNF-a) and interleukin-b1 (ILb1) resulted in mitochondria dysfunction, tissue damage, and cell death (Rege and Hodgkinson, 2013) . Alterations in cytokine levels were proposed to influence mood occurrences and duration in BD (Naaldijk et al., 2016; O'Brien et al., 2006; Soderlund et al., 2011) and as a common biomarker of BD (Altamura et al., 2014) . Other evidence (Brietzke and Kapczinski, 2008) points to elevated concentrations of TNFa in BD as a molecular target for the development of novel treatments. Therefore, inflammation has been thought to be involved in the pathophysiology of, phenomenology of, and treatment response to BD.
We previously reported (Lee et al., 2014b ) that alcohol dependence might be categorized into (i) simple, (ii) anxiety depression, (iii) mixed (bipolar), and (iv) antisocial subtypes with genetic variations in Han Chinese populations. Brief descriptions of each type of alcoholism are listed below: (i) Simple alcoholism is usually onset in middle adulthood. It is associated with no comorbid mental illnesses and fewer alcohol-related problems than are other types. It is similar to Lesch's type I alcoholics (Lesch et al., 1988) . (ii) Anxiety depression alcoholism: In this subtype, patients almost always have comorbid anxiety or depression before, during, or after drinking; this subtype is associated with more severe alcohol use than other types. The onset is during late adolescence or early adulthood. It is similar to Cloninger's type I alcoholism (Cloninger, 1987) . (iii) Antisocial alcoholism: comorbid with antisocial personality disorder; onset is usually during early or middle adolescence; associated with more alcohol-related problems, social consequences, and physical consequences than other types. Alcohol abuse might be a symptom of antisocial behavior. This subtype is similar to Lesch's type IV and Cloninger's type II alcoholism (Cloninger, 1987; Lesch et al., 1988) . (iv) Mixed bipolar alcoholism: alcoholism comorbid with BD or other substance use disorder. This subtype is similar to Lesch's type III and Babor's type B alcoholism (Babor et al., 1992; Lesch et al., 1988) . In our clinical experience, it is more difficult to stop BD patients with the mixed subtype from drinking than it is to stop those with the simple and anxiety depression subtypes. An adequate combination of mood stabilizers plus neuroprotective and anti-inflammatory agents might greatly benefit treatment for BD-II patients with comorbid alcohol dependence.
Memantine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. However, we previously (Wu et al., 2009) reported an alternative mechanism for memantine: It is also an anti-inflammatory agent that downregulates the activity of microglia and up-regulates astrogliareleased of neurotrophic factors, which are mechanistically remote from an NMDA receptor. We found that low-dose (0.02 mg/kg) memantine abolished morphine-induced conditioned-place-preference behavior in rats because of its IL-6-modulating effect in the medial prefrontal cortex (Chen et al., 2012) . We also showed (Lee et al., 2014a ) that low-dose memantine (5 mg/d) added to valproate significantly attenuated plasma cytokine levels in BD-II patients. In addition, add-on memantine in opioid-dependent patients undergoing methadone maintenance treatment not only significantly down-regulated plasma TNF-a levels and up-regulated transforming growth factor-b1 (TGF-b1) levels, but also reduced the methadone dose required (Lee et al., 2015) .
Because memantine might not only inhibit the overactivity of microglia, but also repair damaged neurons and restore neurogenesis by activating astroglia and up-regulating astroglia-released neurotrophic factors, we hypothesize that the neuroprotective and neurotrophic effects of memantine would benefit BD-II patients with comorbid alcohol dependence. In this study, we investigated whether add-on lowdose (5 mg/d) memantine benefits BD-II patients with comorbid alcohol dependence. The outcome measures included clinical severity, units of alcohol use, and levels of cytokine and plasma brain-derived neurotrophic factor (BDNF) expression.
MATERIALS AND METHODS
The Institutional Review Board for the Protection of Human Subjects at National Cheng Kung University Hospital reviewed and approved the research protocol. All participants were given a detailed description of the study before they signed written informed consent forms.
BD-II patients with comorbid alcohol dependence were recruited from outpatient and inpatient settings in Taiwan. All patients were initially evaluated by an attending psychiatrist and then given a structural interview by a clinical psychologist to determine DSM-IV-TR diagnoses, using the Chinese version of the Modified Schedule of Affective Disorder and Schizophrenia-Life Time (SADS-L) (Endicott and Spitzer, 1978) , which has good interrater reliability (Huang et al., 2004) . Patients with major mental illnesses other than BD-II and alcohol dependence and who had taken memantine within 1 week before the study began were excluded. Although DSM-IV-TR criteria require a minimum of 4 days of hypomania, current epidemiologic data (Angst et al., 2010; Benazzi and Akiskal, 2006; Wang et al., 2016) suggest that 2 days is more prevalent in community samples; therefore, we used the 2-day minimum for hypomania to diagnose BD-II.
Study Design
Eligible patients were given low-dose add-on memantine (5 mg/d) after an initial screening, with open-label valproic acid treatment (500 or 1,000 mg/d [50 to 100 lg/ml in plasma]), which began when they joined the study. The severity of mood symptoms was assessed using the Hamilton Depression Rating Scale (HDRS) and the Young Mania Rating Scale (YMRS). Only patients with moderate mood symptoms (HDRS ≥ 18 or YMRS ≥ 14) were recruited. The exact amount of alcohol used by each patient was assessed using the Chinese version of the modified SADS-L. Symptom severity and alcohol use were assessed at baseline, and treatment responses were measured on day 7 of weeks 1, 2, 4, 8, and 12.
Concomitant benzodiazepine medication (lorazepam <8 mg and chlordiazepoxide <240 mg) was used for nighttime sedation and withdrawal symptoms during the study. Up to 20 mg/d of fluoxetine was permitted for associated depressive symptoms and 1 to 3 mg of risperidone for hypomanic symptoms.
Ten milliliters of whole blood was withdrawn from the antecubital vein of each patient when clinical severity was assessed as follows: at baseline and on day 7 of weeks 1, 2, 4, 8, and 12. Plasma, which was isolated from the whole blood after it had been centrifuged at 3,000 9 g for 15 minutes at 4°C, was immediately stored at À80°C. Cytokine levels were quantified using an antibody pair assay system (Flexia; BioSource Intl., Camarillo, CA). Sample processing and data analysis were carried out according to the manufacturer's instructions. The immunological parameters-plasma TNF-a, C-reactive protein (CRP), TGF-b1, IL-8, IL-10, and BDNF-were analyzed.
Statistical Analysis
The demographic and clinical characteristics of the patientsbaseline and end point YMRS and HDRS scores, alcohol use, and cytokine levels-are presented as means AE standard deviation (SD).
The intent-to-treat (ITT) analysis set included all patients who had taken at least 1 dose of a study drug and had undergone 1 baseline assessment and at least 1 postbaseline assessment. All outcome variables-HDRS, YMRS, cytokine levels, plasma BDNF levels, and metabolic parameters-in the ITT set were analyzed. Missing data were filled in using the last observation carried forward method.
The overall within-group changes in each outcome over the 12 weeks were analyzed using generalized estimating equations. We ran 9 models with each outcome as a dependent variable. In each model, treatment duration, gender, and age were included as independent variables, and we controlled for using valproate before the trial, and for using fluoxetine, risperidone, and lorazepam during the trial. The covariance structure used was the autoregressive AR (1) model. The significance of change in each outcome over the 12-week follow-up is represented by the variable "treatment duration." Linear regression analysis was used to analyze correlations between changes in alcohol use and changes in cytokine and BDNF levels during the 12 weeks. Changes in alcohol use were dependent variables, and changes in HDRS and YMRS scores and plasma cytokine and BDNF levels (controlled for gender, age, and baseline clinical severity), and changes in concomitant medicine use were independent variables. SPSS for Windows Inc., Version 22 (Chicago, IL) was used for all statistical computations. Significance was set at p < 0.05.
RESULTS
We initially screened 99 patients: 39 were excluded because they did not meet the inclusion criteria and 15 because they refused to participate. Forty-five BD-II patients with comorbid alcohol dependence were treated with low-dose (5 mg/d) memantine for 12 weeks. Twenty-six (57.8%) of them completed the 12-week follow-up, and 19 (49.6%) dropped out: 17 refused follow-up, and 2 traveled abroad. The flowchart of the study can be seen in Fig. 1 .
Patient's baseline and end point demographic and clinical characteristics, HDRS and YMRS scores, alcohol use, and cytokine and BDNF levels are presented in Table 1 . All patients were treated with lorazepam (mean: 2.89 AE 1.35 mg/d). Six patients had taken valproate (mean: 875 mg/d; range: 500 to 1,000 mg/d; duration: 7.1 weeks) before the beginning of the study. Only 1 patient was treated with fluoxetine during the study, but 32 patients were treated with risperidone. After 12 weeks of treatment, mean withingroup decreases in clinical severity (HDRS and YMRS scores) (p < 0.001), alcohol use (p < 0.001), CRP (p = 0.012), and IL-8 levels (p = 0.021) were significant (Table 2) . BDNF levels were significantly (p = 0.018) higher (Table 2 ). After we had controlled for using valproate before the trial, and for using fluoxetine, risperidone, and lorazepam during the trial, we found no significant correlation between changes in alcohol use levels or HDRS and YMRS scores. The correlation between changes in alcohol use and in TGF-b1 levels, however, was significant (B = 0.003, p = 0.022) (Table 3; Fig. 2) .
Overall, 15 patients (33.3%) stopped drinking during the first week of memantine treatment. After 12 weeks of treatment, all patients had significantly reduced their alcohol use >50%, and 22 patients (84.6%) had reduced their alcohol use to 0 units.
DISCUSSION
Our most important finding was that low-dose (5 mg/d) add-on memantine treatment significantly attenuates clinical severity, reduces alcohol use and plasma cytokine levels, and BDNF, brain-derived neurotrophic factor; CRP, C-reactive protein; HDRS, Hamilton Depression Rating Scale; IL-8, interleukin-8; IL-10, interleukin-10; SD, standard deviation; TGF-b1, transforming growth factor-b1; TNF-a, tumor necrosis factor-a; YMRS, Young Mania Rating Scale. BDNF, brain-derived neurotrophic factor; CRP, C-reactive protein; HDRS, Hamilton Depression Rating Scale; IL-8, interleukin-8; IL-10, interleukin-10; TGF-b1, transforming growth factor-b1; TNF-a, tumor necrosis factor-a; YMRS, Young Mania Rating Scale. † Controlled for using sodium valproate (Depakine) before the trial and for using fluoxetine, risperidone, and lorazepam during the trial. *p < 0.05, **p < 0.001. BDNF, brain-derived neurotrophic factor; CRP, C-reactive protein; HDRS, Hamilton Depression Rating Scale; IL-8, interleukin-8; IL-10, interleukin-10; TGF-b1, transforming growth factor-b1; TNF-a, tumor necrosis factor-a; YMRS, Young Mania Rating Scale. a Controlled for age, gender, and baseline HDRS and YMRS scores, and for using sodium valproate (Depakine) before the trial and for using fluoxetine, risperidone, and lorazepam during the trial. † Controlled for age and gender, and for using sodium valproate (Depakine) before the trial and for using fluoxetine, risperidone, and lorazepam during the trial. *p < 0.05.
up-regulates BDNF levels. We also found a significant correlation between reductions in alcohol use and in plasma TGFb1 levels. Our pilot study provides the first evidence that lowdose add-on memantine for BD-II patients with comorbid alcohol dependence is associated with reduced alcohol use, attenuated clinical symptoms, and down-regulated cytokine levels. We found no correlation between attenuated clinical severity and reduced alcohol use, which indicates that the changes in alcohol use might not be associated with BD-II treatment. One clinical study (Bisaga and Evans, 2004) reported that pretreatment with memantine might reduce craving for alcohol. An animal study (Alaux-Cantin et al., 2015) also reported that, in postdependent (PD) rats, a memantine injection (25 mg/kg) reduced alcohol drinking during acute withdrawal, but that it did not reduce relapses of alcohol dependence after protracted abstinence. However, a doubleblind pilot trial reported that using up to 40 mg/d of memantine (Evans et al., 2007) did not significantly reduce alcohol use compared with placebo. Whether our findings support those of these 3 studies is unclear, because patients were given only 5 mg/d of memantine. Patients' plasma memantine concentrations were about 10 to 50 ng/ml (0.05 to 0.2 lM). This ultralow level of plasma memantine was insufficient to block NMDA receptors (50% inhibition concentration [IC 50 ] of memantine = 2 to 3 lM) (Parsons et al., 1999) .
We previously reported (Wu et al., 2009 ) that low-dose memantine attenuated inflammation by reducing the activity of microglia and up-regulated the release of neurotrophic factors by astroglia, which are mechanistically remote from an NMDA receptor. We hypothesize that the decline in alcohol use in the current study is the result of memantine's antiinflammatory or neurotrophic effect, not its function as an NMDA receptor blocker.
Our subsequent analysis of the changes in alcohol use and changes in cytokine levels yielded a significant correlation between reductions in alcohol use and in plasma TGF-b1 levels. TGF-b1 is a potent anti-inflammatory cytokine that inhibits cytokine production (Yang et al., 2012) . Plasma TGF-b1 levels were higher in alcohol-dependent than in nondependent patients (Kim et al., 2009 ) and rats (Kuhn and Sarkar, 2008) . The increase in TGF-b1 might, however, be a predictor of alcohol-induced liver damage, because TGF-b1 mediates hepatic apoptosis and fibrogenesis, and suppresses hepatocyte proliferation (Schuster and Krieglstein, 2002) . Our finding of a positive correlation between reduced alcohol use and reduced TGF-b1 levels suggests that decreasing one's use of alcohol reduces alcohol-induced liver fibrosis and hepatocyte apoptosis. We hypothesize that the anti-inflammatory and neurotrophic effect of low-dose add-on memantine is involved in reducing plasma TGF-b1 levels, which, in turn, might contribute to reducing alcohol use. However, Kim and colleagues (2009) reported that TGF-b1 levels were not correlated with mean daily alcohol consumption; therefore, the mechanism that TGF-b1 uses to decrease alcohol use requires additional investigation. Our study has some limitations. First, this is a single-arm trial that has no placebo group to compare with the low-dose memantine group. Although we tried to limit concomitant treatment medication to only 2 drugs, it is difficult to confirm that the attenuation of clinical symptoms and reduction in alcohol use is related only to the effect of add-on memantine. However, our review of the literature showed no reports which suggested that sodium valproate (Depakine) attenuated alcohol dependence or alcohol drinking; thus, we inferred that memantine reduced alcohol use and helped treat alcohol dependence. Randomized double-blind trials are required to confirm this. Second, our study sample is small and, typical of BD-II and alcoholism clinical trials, had a high dropout rate. Studies with larger samples are needed to confirm our findings. Third, we sampled only peripheral BDNF and cytokines instead of central nervous system samples because the former samples were easier to obtain. In addition, it has been suggested (Pan and Kastin, 1999; Pan et al., 1998 ) that changes in central BDNF and cytokine levels might be partly reflected by the changes in peripheral levels. Finally, because of our small sample size, if we correct for multiple comparisons using the Bonferroni method, our positive findings of reduced cytokine levels and the correlation between reductions in alcohol use and plasma TGF-b1 levels might not survive. However, if we use the less conservative method, Benjamini-Hochberg method of the false discovery rate (FDR) to correct for multiple comparisons, the significance of our result remains if we set FDR(R) at 0.25. The Q value is = 0.25 9 1/8 = 0.03125, and our result (p = 0.022 < Q value) would survive multiple comparisons.
CONCLUSION
This appears to be the first pilot study which shows that low-dose add-on memantine (5 mg/d) treatment for BD-II patients with comorbid alcohol dependence significantly attenuated clinical severity, reduced alcohol use and plasma cytokine levels, and increased BDNF levels. We also found a significant correlation between reduced alcohol use and reduced plasma TGF-b1 levels. However, we are not able to confirm whether that was related to add-on memantine. Additional studies with larger samples and a randomized double-blind design are required.
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